

News Release

March 1, 2018
Galderma KK
Maruho Co., Ltd.

Maruho Succeeds Manufacturing and Marketing Approval and Marketing Rights for Reduction of Malodor Generated in Cancerous Cutaneous Ulcers Treatment “Rozex® Gel 0.75%”

Osaka and Tokyo (Japan), March 1, 2018 – Maruho Co., Ltd. (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Galderma KK (Head Office: Tokyo, Japan, Representative Director: Tomonori Azuma) announce that from March 1, 2018, Maruho will succeed the manufacturing and marketing approval and marketing rights in Japan from Galderma KK for reduction of malodor generated in cancerous cutaneous ulcers treatment “Rozex® Gel 0.75%” (INN: metronidazole, hereinafter referred to as “Rozex”).

Rozex is the only topical gel in Japan approved for “sterilization of cancerous cutaneous ulcers and reduction of associated malodor”. Malodor associated with cancerous cutaneous ulcers generates from a tumor in advanced cancer and is strong and unique. This strong smell significantly disturbs the quality of life (QOL) of patients and their families. The cause of cancerous cutaneous ulcer malodor is mainly anaerobic bacteria (gram positive and gram negative) in an ulcer lesion. Metronidazole, the active ingredient of Rozex, reduces the odor associated with cancerous cutaneous ulcers by exerting its antibacterial action against anaerobic bacteria. In December 2010, Galderma KK developed Rozex at the request of the Ministry of Health, Labour and Welfare. Galderma KK received manufacturing and marketing approval in December 2014, then began marketing Rozex in May 2015.

Maruho and Galderma Pharma S.A. (“Galderma SA”, Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman) agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of Galderma SA’s prescription drugs for dermatology in Japan. From August 2016, Maruho has appropriately provided and collected medical information for Rozex in Japan. From March 1, 2018, Maruho will appropriately provide and collect information as the manufacturer and distributor of Rozex in Japan and will ensure a stable supply of this product.

As a pharmaceutical company specializing in dermatology, Maruho hopes to further contribute to improving the QOL of cancer patients and their families through the succession of manufacturing and marketing approval and marketing rights for Rozex in Japan.

About Galderma

Galderma, Nestlé Skin Health's medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

For more information, please visit www.galderma.com

About Maruho

Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,459 employees (as of the end of September 2017), and net sales were approximately 79.95 billion yen in its 2017 fiscal year. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.

For more information, please visit www.maruho.co.jp/english

Contact Information:

Galderma KK

Kimimoto Sugino

Tel:+81-(0)3-6628-6616 Fax:+81-(0)3-6628-6659

Email: award.japan@galderma.com

Maruho Co., Ltd.

Corporate Communications Dept.

Roger Matthews

Tel: +81-(0)6-6371-8831 Fax: +81-(0)6-6376-8679

Email: kouhou@mii.maruho.co.jp